Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

canakinumab

A recombinant monoclonal antibody targeting human interleukin-1 beta (IL-1b), with anti-inflammatory and immunomodulating activities. Canakinumab binds IL-1b and prevents the binding of IL-1b to the IL-1 receptor and inhibits IL-1b-mediated signaling. This may suppress inflammatory responses mediated by IL-1b. IL-1b, a proinflammatory cytokine, plays a key role in inflammation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Ilaris
Code name:ACZ885
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search